Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.

Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, Rahl PB, Sun HH, Yeda KT, Doench JG, Reichert E, Kung AL, Rodig SJ, Young RA, Shipp MA, Bradner JE.

Cancer Cell. 2013 Dec 9;24(6):777-90. doi: 10.1016/j.ccr.2013.11.003. Erratum in: Cancer Cell. 2014 Apr 14;25(4):545-6.

2.

Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.

Sengupta D, Kannan A, Kern M, Moreno MA, Vural E, Stack B Jr, Suen JY, Tackett AJ, Gao L.

Epigenetics. 2015;10(6):460-6. doi: 10.1080/15592294.2015.1034416. Epub 2015 May 5.

3.

Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI, Young RA.

Cell. 2013 Apr 11;153(2):320-34. doi: 10.1016/j.cell.2013.03.036.

4.

Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.

Donato E, Croci O, Sabò A, Muller H, Morelli MJ, Pelizzola M, Campaner S.

Leukemia. 2017 Feb;31(2):479-490. doi: 10.1038/leu.2016.182. Epub 2016 Jun 24.

5.

Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.

Ceribelli M, Kelly PN, Shaffer AL, Wright GW, Xiao W, Yang Y, Mathews Griner LA, Guha R, Shinn P, Keller JM, Liu D, Patel PR, Ferrer M, Joshi S, Nerle S, Sandy P, Normant E, Thomas CJ, Staudt LM.

Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11365-70. doi: 10.1073/pnas.1411701111. Epub 2014 Jul 21.

6.

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, Akbay E, Kimmelman AC, Kung AL, Bradner JE, Wong KK.

Clin Cancer Res. 2013 Nov 15;19(22):6183-92. doi: 10.1158/1078-0432.CCR-12-3904. Epub 2013 Sep 17.

7.

BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia.

Roe JS, Mercan F, Rivera K, Pappin DJ, Vakoc CR.

Mol Cell. 2015 Jun 18;58(6):1028-39. doi: 10.1016/j.molcel.2015.04.011. Epub 2015 May 14.

8.

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.

Rathert P, Roth M, Neumann T, Muerdter F, Roe JS, Muhar M, Deswal S, Cerny-Reiterer S, Peter B, Jude J, Hoffmann T, Boryń ŁM, Axelsson E, Schweifer N, Tontsch-Grunt U, Dow LE, Gianni D, Pearson M, Valent P, Stark A, Kraut N, Vakoc CR, Zuber J.

Nature. 2015 Sep 24;525(7570):543-547. doi: 10.1038/nature14898. Epub 2015 Sep 14.

9.

Super-Enhancer-Mediated RNA Processing Revealed by Integrative MicroRNA Network Analysis.

Suzuki HI, Young RA, Sharp PA.

Cell. 2017 Mar 9;168(6):1000-1014.e15. doi: 10.1016/j.cell.2017.02.015.

10.

Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.

Lenhart R, Kirov S, Desilva H, Cao J, Lei M, Johnston K, Peterson R, Schweizer L, Purandare A, Ross-Macdonald P, Fairchild C, Wong T, Wee S.

Mol Cancer Ther. 2015 Oct;14(10):2167-74. doi: 10.1158/1535-7163.MCT-15-0037. Epub 2015 Aug 7.

11.
12.

BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.

Zhang Z, Ma P, Jing Y, Yan Y, Cai MC, Zhang M, Zhang S, Peng H, Ji ZL, Di W, Gu Z, Gao WQ, Zhuang G.

Theranostics. 2016 Jan 1;6(2):219-30. doi: 10.7150/thno.13178. eCollection 2016.

13.

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.

Lockwood WW, Zejnullahu K, Bradner JE, Varmus H.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19408-13. doi: 10.1073/pnas.1216363109. Epub 2012 Nov 5.

14.

Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.

Polo JM, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally JM, Shipp M, Melnick A.

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3207-12. Epub 2007 Feb 20.

15.

Bromodomain inhibition in diffuse large B-cell lymphoma--giving MYC a brake.

Mottok A, Gascoyne RD.

Clin Cancer Res. 2015 Jan 1;21(1):4-6. doi: 10.1158/1078-0432.CCR-14-1651. Epub 2014 Aug 27.

16.

BRAD4 plays a critical role in germinal center response by regulating Bcl-6 and NF-κB activation.

Gao F, Yang Y, Wang Z, Gao X, Zheng B.

Cell Immunol. 2015 Mar;294(1):1-8. doi: 10.1016/j.cellimm.2015.01.010. Epub 2015 Jan 28.

PMID:
25656449
17.

BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.

Parekh S, Polo JM, Shaknovich R, Juszczynski P, Lev P, Ranuncolo SM, Yin Y, Klein U, Cattoretti G, Dalla Favera R, Shipp MA, Melnick A.

Blood. 2007 Sep 15;110(6):2067-74. Epub 2007 Jun 1.

18.

Super enhancers at the miR-146a and miR-155 genes contribute to self-regulation of inflammation.

Duan Q, Mao X, Xiao Y, Liu Z, Wang Y, Zhou H, Zhou Z, Cai J, Xia K, Zhu Q, Qi J, Huang H, Plutzky J, Yang T.

Biochim Biophys Acta. 2016 Apr;1859(4):564-71. doi: 10.1016/j.bbagrm.2016.02.004. Epub 2016 Feb 5.

PMID:
26855180
19.

Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.

Pasqualucci L, Migliazza A, Basso K, Houldsworth J, Chaganti RS, Dalla-Favera R.

Blood. 2003 Apr 15;101(8):2914-23. Epub 2002 Dec 19.

20.

Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition.

Tang Y, Gholamin S, Schubert S, Willardson MI, Lee A, Bandopadhayay P, Bergthold G, Masoud S, Nguyen B, Vue N, Balansay B, Yu F, Oh S, Woo P, Chen S, Ponnuswami A, Monje M, Atwood SX, Whitson RJ, Mitra S, Cheshier SH, Qi J, Beroukhim R, Tang JY, Wechsler-Reya R, Oro AE, Link BA, Bradner JE, Cho YJ.

Nat Med. 2014 Jul;20(7):732-40. doi: 10.1038/nm.3613. Epub 2014 Jun 29.

Supplemental Content

Support Center